Ask AI
ProCE Banner Activity

CE / CME

Myeloma Masterclass: Applying the Latest Guidelines for Evidence-Based, Equitable Care

Video

In this certified on-demand webcast, experts discuss the latest guidelines for the management of newly diagnosed, smoldering, and relapsed/refractory multiple myeloma, including use of bispecific antibodies, antibody–drug conjugates, CAR T-cell therapies, and novel therapeutics. 

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Registered Nurses: 1.50 Nursing contact hour

Physician Assistants: maximum of 1.50 hours of AAPA Category 1 CME credits

Pharmacists: 1.50 contact hours (0.15 CEUs)

ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

Released: June 19, 2025

Expiration: December 18, 2025

Continue Activity

Share

Provided by

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC and Sanofi.

Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC

Sanofi

Partners

Clinical Care Options, LLC

ProCE Banner

Target Audience

This activity is intended for hematologists, oncologists, PAs, nurses, pharmacists, physician associates, and other healthcare professionals who care for patients with multiple myeloma.

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of learners in effort to optimize treatment for patients with multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Initiate timely systemic treatment for appropriate patients based on risk assessment and the latest multiple myeloma diagnostic and staging criteria

  • Develop individualized treatment strategies for patients with newly diagnosed multiple myeloma through consideration of the available clinical data as well as NCCN Guidelines, risk assessment, comorbidities, and patient age/fitness and preferences

  • Select optimal sequencing and bridging therapies for patients with relapsed/refractory multiple myeloma based on individual patient and disease characteristics, as well as NCCN Guideline recommendations and response to and tolerance of previous therapies

  • Appraise the latest clinical data for current and emerging therapies/regimens for patients with multiple myeloma

  • Implement strategies to improve access, quality of care, and equitable clinical trial enrollment for all patients with multiple myeloma

Disclosure

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers, ​and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.​

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Definitions 
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients. ​

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.​

Faculty Disclaimers  
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.​

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Primary Author

Natalie S. Callander, MD, has no relevant conflicts of interest to disclose.

Carol Ann Huff, MD: consultant/advisor/speaker: Bristol Myers Squibb, Legend Biotechnologies, Prothena, Sanofi.

Shaji Kumar, MD: consultant: AbbVie, Amgen, ArcellX, BeiGene, BD Biosciences, Bristol Myers Squibb, CARsgen, GlaxoSmithKline, Janssen, K36, Moderna, Pfizer, Regeneron, Roche/Genentech, Sanofi, Takeda; researcher (paid to institution): AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, CARsgen, GlaxoSmithKline, Gracell Bio, Janssen, Oricell, Roche/Genentech, Sanofi, Takeda, Telogenomics.

NCCN and CCO Staff Disclosures
None of the other planners/managers for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 19, 2025, through December 18, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

NCCN designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

NCCN designates this educational activity for a maximum of 1.5 contact hours. This activity offers 1.5 pharmacotherapeutic contact hours for nurses. 

Continuing Pharmacy Education

NCCN designates this knowledge-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-25-096-H01-P 

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days. 

Physician Associate Continuing Medical Education

LogoDescription automatically generated

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until December 18, 2025. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification

 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregated participant data will be shared with the commercial supporters of this activity.​

For ABIM MOC points, your information will be shared with the ABIM through NCCN’s Joint Accreditation Program and Activity Reporting System (JA-PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.​

By sharing your Diplomate Board ID # and DOB, you are giving NCCN permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).